The Week

ATYR Pharma fell 29.33% this week, closing at $0.174 against a 1.95% drop for the S&P 500, underperforming the benchmark by roughly 27.38 percentage points. The stock slid in a single direction across the week: Monday (Oct 12) opened at $0.2477 and drifted lower, Tuesday (Oct 13) broke below $0.22, Wednesday (Oct 14) touched $0.1807, and Friday (Oct 16) closed at the week’s low of $0.174. There was no major corporate announcement or earnings during the week. Average daily volume of 2.26m shares ran about 143% above the 60-day median of 0.93m. The stock marked a fresh 60-day range low.

Analyst Ratings

Coverage stands at 9 firms: 2 strong buy, 2 buy, 5 hold, with no underperform or sell ratings. The consensus rating is buy, and the consensus target price is $2.857, sitting about 1,542% above the latest price of $0.174. Individual targets range from $1.000 to $7.000, pointing to wide dispersion. Within the biotechnology industry, the stock ranks 160th out of 509 names.

The Week Ahead

No ATYR-specific earnings or corporate events are on the calendar for next week. On the macro side, the US NAHB housing market index is due Monday (Oct 19), with prior and forecast both at 32. Tuesday (Oct 20) brings housing starts annualised (prior 1.275, forecast 1.305) and building permits annualised (prior 1.403, forecast 1.395). The week’s news on ATYR0101’s anti-fibrotic effects and the special stockholder meeting leaves room for follow-up clinical or management disclosures to watch.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.